Teva Pharmaceutical Industries (TEVA) Payables (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Payables for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 8.93% year-over-year to $2.7 billion; the trailing twelve-month figure through Jun 2026 stood at $2.7 billion (up 8.93% YoY), and the FY2025 full-year result was $2.5 billion, up 14.89% from the prior year.
• Payables improved to $2.7 billion in Q2 2026 per TEVA's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Payables topped out at $2.7 billion in Q2 2026 and bottomed at $1.6 billion in Q3 2022.
• Historically, Payables has averaged $2.3 billion across 5 years, with a median of $2.4 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Payables jumped 39.45% in 2023, then slipped 15.33% in 2024.
• Over 5 years, Payables stood at $1.9 billion in 2022, then jumped by 37.89% to $2.6 billion in 2023, then retreated by 15.33% to $2.2 billion in 2024, then increased by 14.89% to $2.5 billion in 2025, then gained by 7.51% to $2.7 billion in 2026.
• According to Business Quant data, Payables over the past three periods registered $2.7 billion, $2.6 billion, and $2.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.